Bristol-Myers Squibb (BMY) is one of the best value stocks for 2023
The bear market has been downright brutal for growth stocks. Thus, it is clear that now is the time for value. That's why you need to find out the attractiveness of Bristol-Myers Squibb (BMY) stocks. Read below for the full story.
shutterstock.com - StockNewsBristol-Myers Squibb (BMY) is the headliner of a stock to hold during a bear market. First, because it's in the defensive healthcare sector that doesn't falter when the economy is under pressure. Second, the north of 3% dividend yield is a welcome sight when your bank account isn't earning cash.
Add it all up and you'll see why stocks were in positive territory in 2022 when most other stocks were painted red. Thankfully the market outlook is still bleak due to the impending recession, BMY continues to be a great choice for the year ahead.
As noted above, healthcare is still a safe haven for investors amid recession and growing pains, as most people will sacrifice spending elsewhere to stay on track. This notion shows up quite clearly in their long term winning track record with only 1 miss in the last 20 quarters. And that includes 4 consecutive beats in 2022.
On the POWR ratings front, it is full of high ratings that indicate strong price action to come. This party starts with A overall + A for Value. After that you have a series of Bs for stability, feeling and quality.
Stability indicates lower beta and better nights sleep during tough times. While Quality says it is an extremely well-managed company that is likely to continue to produce positive results in the future.
Just for good measure, BMY offers healthy income to support growth and value. When the cash is doing next to nothing, it certainly helps the ROI story when you add a nearly 3% dividend yield into the mix.
This really is an all-weather value title. But especially beneficial to consider when bearish storm clouds are still in the air.
Want to check out more valuable stocks?
BMY is just one of 7 attractive value stocks found in a new special report we just wrote. Click the link below to claim your free copy now:
7 SERIOUSLY undervalued stocks
What to do next?
Watch my brand new presentation: "2023 Stock Market Outlook" covering:
Why 2023 is a "Jekyll & Hyde" year for stocks 5 warnings signal the return of the bear in early 2023 8 Profitable Trades on the Way Down Plan to melt the fish at the bottom of the market 2 trades with 100%+ upside potential as a new bull emerges And much more!Watch now: "Stock market outlook 2023" >
Wishing you a world of investing success!
Steve Reitmeister…but everyone calls me Reity (pronounced “Righty”)CEO, Stock News Network and Editor, Reitmeister Total Return
BMY shares were trading at $71.65 per share on Thursday afternoon, down $0.29 (-0.40%). Year-to-date, BMY has gained 0.37%, compared to a 4.02% rise in the benchmark S&P 500 over the same period.
Steve is better known to the StockNews audience as "Reity". Not only is he the CEO of the company, but he also shares his 40 years of investment experience in the Reitmeister Total Return portfolio. Learn more about Reity's journey, plus links to his most recent articles and stock picks.
More...
The Bristol-Myers Squibb (BMY) publication is a high value stock for 2023 appeared first on StockNews.com
The bear market has been downright brutal for growth stocks. Thus, it is clear that now is the time for value. That's why you need to find out the attractiveness of Bristol-Myers Squibb (BMY) stocks. Read below for the full story.
shutterstock.com - StockNewsBristol-Myers Squibb (BMY) is the headliner of a stock to hold during a bear market. First, because it's in the defensive healthcare sector that doesn't falter when the economy is under pressure. Second, the north of 3% dividend yield is a welcome sight when your bank account isn't earning cash.
Add it all up and you'll see why stocks were in positive territory in 2022 when most other stocks were painted red. Thankfully the market outlook is still bleak due to the impending recession, BMY continues to be a great choice for the year ahead.
As noted above, healthcare is still a safe haven for investors amid recession and growing pains, as most people will sacrifice spending elsewhere to stay on track. This notion shows up quite clearly in their long term winning track record with only 1 miss in the last 20 quarters. And that includes 4 consecutive beats in 2022.
On the POWR ratings front, it is full of high ratings that indicate strong price action to come. This party starts with A overall + A for Value. After that you have a series of Bs for stability, feeling and quality.
Stability indicates lower beta and better nights sleep during tough times. While Quality says it is an extremely well-managed company that is likely to continue to produce positive results in the future.
Just for good measure, BMY offers healthy income to support growth and value. When the cash is doing next to nothing, it certainly helps the ROI story when you add a nearly 3% dividend yield into the mix.
This really is an all-weather value title. But especially beneficial to consider when bearish storm clouds are still in the air.
Want to check out more valuable stocks?
BMY is just one of 7 attractive value stocks found in a new special report we just wrote. Click the link below to claim your free copy now:
7 SERIOUSLY undervalued stocks
What to do next?
Watch my brand new presentation: "2023 Stock Market Outlook" covering:
Why 2023 is a "Jekyll & Hyde" year for stocks 5 warnings signal the return of the bear in early 2023 8 Profitable Trades on the Way Down Plan to melt the fish at the bottom of the market 2 trades with 100%+ upside potential as a new bull emerges And much more!Watch now: "Stock market outlook 2023" >
Wishing you a world of investing success!
Steve Reitmeister…but everyone calls me Reity (pronounced “Righty”)CEO, Stock News Network and Editor, Reitmeister Total Return
BMY shares were trading at $71.65 per share on Thursday afternoon, down $0.29 (-0.40%). Year-to-date, BMY has gained 0.37%, compared to a 4.02% rise in the benchmark S&P 500 over the same period.
Steve is better known to the StockNews audience as "Reity". Not only is he the CEO of the company, but he also shares his 40 years of investment experience in the Reitmeister Total Return portfolio. Learn more about Reity's journey, plus links to his most recent articles and stock picks.
More...
The Bristol-Myers Squibb (BMY) publication is a high value stock for 2023 appeared first on StockNews.com
What's Your Reaction?
